97117501 - PRECISION BIOSCIENCES

Information

• Trademark
• 97117501

• Source

• Serial Number

  97117501

• Registration Number

  7034223

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  November 10, 2021
  3 years ago

• Registration Date

  April 25, 2023
  2 years ago

• Transaction Date

  May 08, 2023
  2 years ago

• Status Date

  April 25, 2023
  2 years ago

• Published for Opposition Date

  December 20, 2022
  2 years ago

• Location Date

  April 25, 2023
  2 years ago

• First Use Anywhere Date

  February 25, 2016
  9 years ago

• First Use In Commerce Date

  February 25, 2016
  9 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  BUSH, KAREN K

• Attorney Docket Number

  30304-00002

  Attorney Name

  Eva Gullick Frongello

  Law Office Assigned Location Code

  L80

• Owners

  • Precision Biosciences, Inc.

Case File Statements

• GS0051: pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use
• GS0011: genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno
• GS0441: Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer
• D10000: "BIOSCIENCES"
• GS0421: research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer

Case File Event Statements

• 5/8/2023 - 2 years ago

  26 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 5/8/2023 - 2 years ago

  25 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 5/8/2023 - 2 years ago

  24 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 5/8/2023 - 2 years ago

  23 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 5/8/2023 - 2 years ago

  22 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 4/25/2023 - 2 years ago

  21 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 4/25/2023 - 2 years ago

  20 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 3/6/2023 - 2 years ago

  19 - ATTORNEY REVIEW COMPLETED Type: ATRV

• 3/6/2023 - 2 years ago

  18 - LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN Type: LOPR

• 3/6/2023 - 2 years ago

  17 - JURISDICTION RESTORED TO EXAMINING ATTORNEY Type: JURT

• 3/1/2023 - 2 years ago

  16 - EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Type: ETOP

• 1/18/2023 - 2 years ago

  15 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF

• 12/20/2022 - 2 years ago

  14 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/20/2022 - 2 years ago

  13 - PUBLISHED FOR OPPOSITION Type: PUBO

• 12/15/2022 - 2 years ago

  12 - LETTER OF PROTEST EVIDENCE FORWARDED Type: LOPT

• 11/30/2022 - 2 years ago

  11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/17/2022 - 2 years ago

  10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/2/2022 - 2 years ago

  9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/2/2022 - 2 years ago

  8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/2/2022 - 2 years ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 5/12/2022 - 3 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/12/2022 - 3 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 5/12/2022 - 3 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 5/10/2022 - 3 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 11/17/2021 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 11/13/2021 - 3 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP